Astellas Pharma has initiated a global campaign to address the critical issue of delayed bladder cancer diagnoses. In collaboration with the World Bladder Cancer Patient Coalition (WBCPC) and behavioral scientists, the company aims to understand the barriers preventing individuals from seeking timely medical attention for bladder cancer symptoms.
Bladder cancer often goes undetected until advanced stages, significantly reducing survival rates. By exploring cultural, emotional, and societal factors influencing patient behavior, Astellas seeks to develop strategies that encourage earlier diagnosis and improve outcomes for those affected by this disease.
This initiative underscores Astellas’ commitment to patient-centric approaches and aligns with the broader efforts within the Leiden Bio Science Park to enhance healthcare through innovative research and collaboration.
Read more here
A joint effort between Leiden University's Professor Ubbink's lab and ZoBio's Assay Development and Screening team has advanced fragment-based drug discovery targeting membrane...
Researchers at Leiden University Medical Center (LUMC), in collaboration with Erasmus MC and the Oncode Institute, have developed a novel vaccine targeting non-small cell lung...
Leiden University Medical Center (LUMC) has achieved a national milestone by treating the first Dutch patient with an autoimmune disease using CAR-T cell therapy. This approach,...